CD8A and neoplasm: Another study by Jia K et al. explored the relationship between CLDN18.2 expression, clinicopathological characteristics, and immunotherapy outcomes in GC patients, finding that CLDN18.2-positive tumours had a significantly higher fraction of CD8 + T cells than CLDN18.2-negative tumours [20].